The U.S. has added additional Chinese companies to its Entity List and Unverified List; China's State Council has taken steps to encourage foreign venture capital in the tech sector; and Chinese electrolyzer manufacturers are "Europeanizing" their products in anticipation of an EU crackdown.
The U.S. publishes details on "Reverse CFIUS;" Shein's London listing might face obstacles; and two of the top 10 VC deals globally involve China, with much of the funding coming from Chinese state-backed investors.
State Council prohibits policy measures that are against fair competition. Securities Association of China revises rules on alternative investment subsidiaries and private investment fund subsidiaries of securities companies.
Alleged receiving of kickbacks by senior executives in China could subject Adidas to Chinese, as well as German and U.S. investigations; U.S. convertible bond market is used to raise funds by Chinese big tech amid IPO restrictions; and EU tariffs may lead to localization of Chinese EV production.
SPC Interpretation protects prepaid consumption against improper standard clauses. Shanghai and Shenzhen Stock Exchanges specify the reporting requirements for programmed trading. CSRC requires repurchase of illegal shareholding reductions.
International investors find Chinese secondary PE market an alternative amid U.S.-China tensions; QuantumPharm is the first IPO under Hong Kong's new measure for pre-revenue specialist technology firms; and China releases new carbon measuring standards foreseeing new EU carbon tariffs.
Apple wins antitrust case in China over app store fees; Temu is now subject to stricter EU online content rules; and Record Chinese investments flow into Mexico and Vietnam amid Western trade tensions.
Data security risk assessments are required for data processing activities by key data and core data handlers in the industry and information technology sector. Requirements applicable to AI service providers in respect of the security of data sources are set forth. The shareholders of a listed company may not lend shares through refinancing or short sell shares of the company during the lockup period.
Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Lingang Special Area of the Shanghai FTZ elaborates on the general data of the biomedical, intelligent connected vehicle and public fund sectors
